Enzictra - DS Tablet is a combination pharmaceutical formulation containing Bromelain (180 mg), Trypsin (96 mg), Rutoside (200 mg), and Papain (120 mg), designed to provide potent anti-inflammatory, proteolytic, and antioxidant effects. Bromelain and Papain are proteolytic enzymes that facilitate the breakdown of proteins, thereby aiding in the reduction of inflammation, edema, and promoting tissue repair in various inflammatory and traumatic conditions. Trypsin, another proteolytic enzyme, enhances the anti-inflammatory action by modulating the inflammatory response and accelerating wound healing. Rutoside, a bioflavonoid, exhibits strong antioxidant properties and contributes to vascular protection by strengthening capillary walls, reducing capillary permeability, and preventing microvascular damage. The synergistic action of these components makes Enzictra - DS Tablet effective in managing conditions such as post-operative swelling, sports injuries, musculoskeletal inflammation, and chronic venous insufficiency. It is also utilized as an adjunct in the treatment of burns, hematomas, and other soft tissue injuries. Enzictra - DS should be administered under medical supervision, considering contraindications such as hypersensitivity to proteolytic enzymes and bleeding disorders. This formulation supports accelerated recovery by mitigating inflammation and oxidative stress, thereby improving patient outcomes in inflammatory and traumatic conditions.